← ANALYST RATINGS · TIPRANKS
Palvella Therapeutics (PVLA): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $236, the highest $267, the lowest $207. The average is +96.1% from the last price of $120.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $135 → $126−6.7% | Hold | +4.7% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $135 → $126−6.7% | Hold | +4.7% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $134 → $125−6.7% | Hold | +3.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $132 → $123−6.8% | Hold | +2.2% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $142 → $133−6.3% | Buy | +10.6% | Upgrade | 17.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $139 → $131−5.8% | Hold | +8.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | — | Buy | — | Reiterated | 16.10.26on TipRanks 09:12 | −4.4% | ↗ |
| Sharon Zackfia★★★★★★★★★★#4054 · hits 44% · avg +3.0% | William Blair | $266 | Buy | +121.1% | Initiated | 15.10.26on TipRanks Oct 16 05:55 | +3.6%next day −4.4% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $215 | Buy | +78.7% | Reiterated | 12.10.26on TipRanks 17:58 | −4.4%next day −3.5% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $270 → $246−8.9% | Buy | +104.5% | Reiterated | 12.10.26on TipRanks 06:30 | −3.1%next day −4.4% | ↗ |
| Name not given | — | $240 | Buy | +99.5% | Reiterated | 21.09.26on TipRanks 06:25 | +0.3%next day +3.1% · 5 days −7.8% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $240 | Buy | +99.5% | Reiterated | 10.09.26on TipRanks 10:50 | 0.0%next day −1.0% · 5 days +2.0% | ↗ |
| Trevor Allred★★★★★★★★★★#291 · hits 87% · avg +84.0% | Oppenheimer | $210 | Buy | +74.6% | Reiterated | 05.08.26on TipRanks 08:35 | +2.1%next day +0.2% · 5 days −0.2% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $225 → $236+4.9% | Buy | +96.2% | Reiterated | 05.08.26on TipRanks 08:10 | +2.1%next day +0.2% · 5 days −0.2% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $210 → $207−1.4% | Buy | +72.1% | Reiterated | 05.08.26on TipRanks 07:55 | +2.1%next day +0.2% · 5 days −0.2% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $227 → $232+2.2% | Buy | +92.9% | Reiterated | 05.08.26on TipRanks 07:20 | +2.1%next day +0.2% · 5 days −0.2% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $267 | Buy | +121.9% | Reiterated | 04.08.26on TipRanks Aug 5 02:55 | +6.2%next day +2.1% · 5 days +1.6% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $250 | Buy | +107.8% | Reiterated | 24.06.26on TipRanks 06:50 | +9.4%next day +4.8% · 5 days +4.8% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | $205 | Buy | +70.4% | Reiterated | 22.06.26on TipRanks 09:45 | +5.4%next day +1.3% · 5 days +30.7% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $220 | Buy | +82.9% | Initiated | 11.05.26on TipRanks May 12 05:25 | +0.4%next day +3.2% · 5 days −13.9% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $200 → $220+10.0% | Buy | +82.9% | Reiterated | 02.03.26on TipRanks Mar 1 17:30 | −1.8%next day +0.1% · 5 days +4.3% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $143 → $209+46.2% | Buy | +73.7% | Reiterated | 24.02.26on TipRanks 14:00 | +36.4%next day +6.0% · 5 days +10.2% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $200 → $210+5.0% | Buy | +74.6% | Reiterated | 15.12.25on TipRanks 10:50 | −9.6%next day +9.1% · 5 days +21.7% | ↗ |
| Dev Prasad★★★★★★★★★★#663 · hits 80% · avg +91.6% | Lucid Capital | $122 → $212+73.8% | Buy | +76.2% | Reiterated | 15.12.25on TipRanks 10:15 | −9.6%next day +9.1% · 5 days +21.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Palvella Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $235 at a price of $138 (+70.5%); now: $236 at $120 (+96.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 32 | 28 | 28 | 17 | 13 | 9 |
| Buy | 2 | 1 | 2 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.79 (from $-2.31 to $-1.05). Last quarter: $-1.52.
Best top-analyst consensus in the sector · Healthcare
About Palvella Therapeutics
- CEO: Wesley H. Kaupinen
- Employees: 29
- 353 W. Lancaster Avenue, Wayne, PA, 19087, US
- palvellatx.com
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗